Abstract Library

#4594 RNA splicing as a key regulatory player with translational potential in pulmonary neuroendocrine neoplasms (lungNETs)

Introduction: Neuroendocrine tumours (NETs) are a diverse group of neoplasms arising from neuroendocrine cells. Within this group, lung neuroendocrine tumours (LungNETs) represent one of the most frequent subtypes of NETs. LungNETs are classified by grade, according to their proliferative index and aggressiveness. Among them, typical carcinoids (G1) and atypical carcinoids (G2) are the lowest grade subtypes. While these tumours are less aggressive, they remain underexplored compared to higher-grade subtypes, highlighting the need for molecular studies to improve clinical approaches. In this context, previous studies have shown that abnormalities in the splicing machinery are frequent in tumour pathologies and also occur in LungNETs.

Conference:

Presenting Author:

Authors: Gutiérrez Camacho L, Ruiz-Palacios D, García Vioque V, González-Pérez C, Moreno Montilla M,

Keywords: splicing, neuroendocrine tumour, Lung NET, typical carcinoid, atypical carcinoid,

#4095 CAPTEM and PRRT to improve overall response for pancreatic NETs (pNETs) – The CORONET trial

Introduction: Patients with advanced pNETs have limited treatment options. The NETTER-2 and OCLURANDOM trials have established peptide receptor radionuclide therapy (PRRT) as a standard treatment in pNETs; CAPTEM chemotherapy is an active regimen in NENs. The CONTROL NETs trial has shown promising response rate and progression-free survival with PRRT+CAPTEM, warranting further investigation.

Conference:

Presenting Author:

Authors: Chan D, Doherty M, Singh S, Michael M, Kong G,

Keywords: PRRT, CAPTEM, Randomized Trial, Phase III,

#3768 Predictive transcriptomic signature of response to axitinib in patients with advanced NETs included in the randomized, double-blind, placebo-controlled AXINET trial (GETNE 1107)

Introduction: Axitinib in combination with Octreotide LAR significantly improved ORR (13.2 vs 3.2%, OR 4.58, p=0.0045) and PFS (16.6 vs 9.9m, HR 0.71, p=0.017) per central blinded radiological assessment, as compared to placebo and SSA, in 256 patients with EP-NETs included in the AXINET trial (Garcia-Carbonero et al, ESMO 2021). The magnitude of the benefit, however, was limited.

Conference:

Presenting Author: Lens-Pardo A

Authors: Lens-Pardo A, Carretero C, Antón-Pascual B, Capdevila J, Benavent M,

Keywords: Axitinib, Tyrosine kinase inhibitor, predictive biomarker, signature,

#3534 Avelumab in unresectable/metastatic, progressive, grade 2-3 neuroendocrine neoplasms (NENs): Translational results from NET-001 and NET-002 trials

Introduction: The role of immunotherapy (IO) and predictive biomarkers in NENs patients remains unclear.

Conference:

Presenting Author: Rodriguez Freixinos V

Authors: Rodriguez-Freixinos V, Bruce J, Chan D, Nunez-Rodriguez J, Mackenzie D,

Keywords: neuroendocrine, cell, research, immunotherapy,

#3398 Patient-derived tumoroids phenocopy original gastro-entero-pancreatic neuroendocrine neoplasms and facilitate in vitro drug screening

Introduction: GastroEnteroPancreatic Neuroendocrine Neoplasms (GEP-NENs) are rare cancers that appear clinically and biologically extremely heterogenous. While highly proliferative cases are invariably lethal, slower-proliferating NENs—representing predominant cases—have unpredictable clinical courses varying from indolent to malignant. Recent comprehensive NGS screens in patients helped to extend our understanding. However, complementary relevant preclinical models to address disease heterogeneity and to investigate patient-specific treatment alternatives are still inexistent.

Conference:

Presenting Author: April-Monn S

Authors: April-Monn S, Kirchner P, Detjen K, Gloor B, Partelli S,

Keywords: GEP-NEN, Organoid, Tumoroid, Model, Drug screening, translational, single-cell RNAseq, NGS, OMICs, biomarker,